This case highlights the contradictions and concerns in executing corporate responsibility programs from the viewpoint of a worldwide biotechnology company.
PUBLICATION DATE: January 01, 2010 PRODUCT #: 910801-VID-ENG
This is just an excerpt. This case is about STRATEGY & EXECUTION
Related Case Solutions & Analyses:
Starbucks: Schultz Back in the Brew
Merck: Managing Vioxx (C)
Filling a Hole: The Reinvestment Fund and Progress Plaza
International Use of the Myers-Briggs Type Indicator
The Rise and fall of Nokia
Henry Schein Doing Well By Doing Good?
NEDBANK: COACHING CAPABILITIES FOR GROWTH EXECUTION
HOLA-KOLA – The Capital Budgeting Decision
ISM Analytics
General Mills Financial Analysis
